Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)

The Carcinogen Hazard Assessment Monographs Program (CHAMP), administered by the National Cancer Institute (NCI) under the U.S. Department of Health and Human Services, aims to support scientific evaluations of carcinogenic hazards to humans. This program is established to generate authoritative monographs that systematically assess scientific evidence related to potential human carcinogens. These assessments are essential for guiding cancer research, influencing regulatory decisions, and supporting public health policies aimed at cancer prevention and control. CHAMP invites applications under a Research Project Grant (R01) mechanism, with clinical trials not permitted under this funding opportunity. The program supports projects that critically analyze mechanistic, toxicological, epidemiological, and other relevant lines of evidence to evaluate the carcinogenic potential of various agents. These evaluations are expected to result in monographs that can serve as critical references for stakeholders involved in health risk assessment, policy formation, and cancer prevention strategies. This funding opportunity is discretionary and open to a wide array of applicants, including federally recognized and non-federally recognized tribal governments and organizations, small and large businesses, nonprofits (with and without 501(c)(3) status), educational institutions, and government entities at the state, county, and regional levels. Foreign institutions and federal agencies are also eligible, reflecting the broad scientific scope and potential international relevance of the research outputs. Cost sharing or matching is not required for this opportunity. Applicants should prepare to submit their proposals electronically through Grants.gov. Although detailed application components and review criteria are not included in this forecast, standard NIH R01 application requirements and peer review processes can be expected. Applicants are advised to check the official NOFO upon its release for comprehensive submission instructions. The estimated key dates for the program include a posting date of February 14, 2026, an application due date of June 30, 2026, and an anticipated award and project start date of October 1, 2026. The funding announcement currently represents a forecast, indicating that final details may be updated upon official release. For questions regarding this opportunity, applicants may contact Tram Kim Lam at the National Cancer Institute via phone at 240-276-6967 or by email at [email protected].